Biotechnology · NASDAQ
当前价格
$52.56
内在价值
使用下方计算器估算
对 Moderna, Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Earnings Yield
-13.70%
ROE (TTM)
-30.1%
基于过去 12 个月的数据，MRNA 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
MRNA 的过去 12 个月市盈率为 可在计算器中查看。该估值指标反映投资者为 Moderna, Inc. 每一美元收益所支付的价格。使用 MiniValuator 的 PE 计算器进行详细分析。
MRNA 是否被高估取决于将其市盈率与行业同类公司、历史均值和增长预期进行比较。高于行业平均的市盈率可能表明被高估，但高成长性公司通常有更高的市盈率。在 MiniValuator 上运行完整估值来分析。
使用市盈率对 MRNA 估值：将其当前 PE 与行业平均值比较，分析 PEG 比率进行增长调整估值，查看历史 PE 区间，并通过目标 PE 乘以 EPS 估算公允价值。MiniValuator 的 PE 计算器可自动完成此分析。
MRNA 的 PEG 比率为 可在计算器中查看。PEG 比率将市盈率除以盈利增长率——PEG 低于 1.0 可能表明股票相对于其增长被低估，是一个有用的辅助估值指标。
PE 市盈率提供快速的相对估值——MRNA 与同类公司的比较。DCF 提供绝对估值——基于预期现金流的股票内在价值。建议同时使用两种方法进行综合估值。MiniValuator 同时提供 PE 和 DCF 计算器。
